{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-055203","form_type":"8-K","ticker":"IDXX","cik":"0000874716","company_name":"IDEXX LABORATORIES INC /DE","filed_at":"2026-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.844917+00:00","generated_at":"2026-05-14T23:41:53.713612+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"IDEXX Q1 beats: rev $1.14B (+14%), EPS $3.47 (+17%); raises FY guidance","bullets":["Q1 revenue $1,141M (+14% as reported, +11% organic); EPS $3.47 (+17% as reported, +15% comparable).","CAG Diagnostics recurring revenue +14% as reported, +11% organic; premium instrument installed base +12%.","FY2026 revenue guidance raised $42M at midpoint to $4,675-$4,760M; EPS guidance to $14.45-$14.90.","Organic revenue growth guidance raised to 7.7%-9.7% from 7.0%-9.0%; operating margin expansion 50-90 bps.","CEO Jay Mazelsky to transition; Mike Erickson will continue as a key leader (mentioned in earnings release)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-055203","json":"https://secwatch.observer/filing/0001104659-26-055203.json","markdown":"https://secwatch.observer/filing/0001104659-26-055203.md","text":"https://secwatch.observer/filing/0001104659-26-055203.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874716/000110465926055203/0001104659-26-055203-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874716/000110465926055203/tm2613510d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:41:53.713612+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"777b60dd847fe7adc77a5f6963f3fbb4815e0cc0","claim":"IDEXX LABORATORIES INC /DE reported the quarter ended March 31, 2026 results: revenue $1,141 million, EPS $3.47. Guidance raised.","evidence_excerpt":"Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. First Quarter Results The Company reports revenues of $1,141 million for the first quarter of 2026, an increase of 14% as reported and 11% organic, driven by Companion Animal Group (\"CAG\") growth of 15% as reported and 12% organic. First quarter","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/874716/000110465926055203/0001104659-26-055203-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Revenue","value":"$1,141 million"},{"label":"EPS","value":"$3.47"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}